NEW YORK (360Dx) – Accelerate Diagnostics said after the close of the market on Monday it has commenced an underwritten public offering of 2.5 million shares of its common stock.

Accelerate has not yet priced the offering, but said in a document filed with the US Securities and Exchange Commission that net proceeds from the offering are estimated at about $68.6 million, based on an assumed public offering of $29.50 per share, the closing price of the company's shares on May 5. The firm plans to use net proceeds for general corporate purposes and to fund commercialization efforts.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.